Marques Vanessa Daccach, Passos Giordani Rodrigues Dos, Mendes Maria Fernanda, Callegaro Dagoberto, Lana-Peixoto Marco Aurélio, Comini-Frota Elizabeth Regina, Vasconcelos Cláudia Cristina Ferreira, Sato Douglas Kazutoshi, Ferreira Maria Lúcia Brito, Parolin Mônica Koncke Fiuza, Damasceno Alfredo, Grzesiuk Anderson Kuntz, Muniz André, Matta André Palma da Cunha, Oliveira Bianca Etelvina Santos de, Tauil Carlos Bernardo, Maciel Damacio Ramón Kaimen, Diniz Denise Sisteroli, Corrêa Eber Castro, Coronetti Fernando, Jorge Frederico M H, Sato Henry Koiti, Gonçalves Marcus Vinícius Magno, Sousa Nise Alessandra de C, Nascimento Osvaldo J M, Gama Paulo Diniz da, Domingues Renan, Simm Renata Faria, Thomaz Rodrigo Barbosa, Morales Rogério de Rizo, Dias Ronaldo Maciel, Apóstolos-Pereira Samira Dos, Machado Suzana Costa Nunes, Junqueira Thiago de Faria, Becker Jefferson
Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Hospital das Clínicas de Ribeirão Preto, Ribeirão Preto SP, Brasil.
Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre RS, Brasil.
Arq Neuropsiquiatr. 2018 Aug;76(8):539-554. doi: 10.1590/0004-282X20180078.
The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main focus on the choice and management of DMTs, as well as present a review of the scientific rationale supporting therapeutic strategies in MS.
多发性硬化症（MS）中不断扩大的治疗手段使得治疗更加有效且个性化，但疾病修正疗法（DMTs）的选择和管理正变得日益复杂。在此背景下，巴西多发性硬化症治疗与研究委员会以及巴西神经病学学会神经免疫学科学部的专家们齐聚一堂，基于他们的认识，即神经科医生应能够根据最新证据和实践，依据对每位患者更有利的情况来开具MS DMTs处方，从而制定了这份巴西MS治疗共识。我们在此提出MS治疗的实用建议，主要聚焦于DMTs的选择和管理，并对支持MS治疗策略的科学依据进行综述。
